Proxima Bio is a venture-backed biotechnology company developing the next generation of medicines, cell surface degraders. Our technology provides new opportunities to target previously undruggable, disease-causing proteins, with powerful potential applications in autoimmune conditions and cancers.

Why work with us

Proxima Bio is an exciting pre-clinical company with a degrader platform capable of targeting several disease-causing proteins.

Our lead assets have great promise in oncology and autoimmune diseases and we are looking to work with like-minded investors and pharmaceutical partners to bring our technology to market.